Claire Milthorpe

Claire Milthorpe

Auto-generated profile, based on publicly available information

Claire Milthorpe

Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Immunity
Verified
Journal Article
Open access
DBDeborah L. Burnett
Deborah L. Burnett
KJKatherine J.L. Jackson
Katherine J.L. Jackson
DLDavid B. Langley
David B. Langley
AAAnupriya Aggarwal
Anupriya Aggarwal
ASAlberto Ospina Stella
Alberto Ospina Stella
CGChristopher C. Goodnow
Christopher C. Goodnow
Viral mutations are an emerging concern in reducing SARS-CoV-2 vaccination efficacy. Second-generation vaccines will need to elicit neutralizing antibodies against sites that are evolutionarily conserved across the sarbecovirus subgenus. Here, we immunized mice containing a human antibody repertoire with diverse sarbecovirus receptor-binding domains (RBDs) to identify antibodies targeting conserved sites of vulnerability. Antibodies with broad reactivity against diverse clade B RBDs targeting the conserved class 4 epitope, with recurring IGHV/IGKV pairs, were readily elicited but were non-neutralizing. However, rare class 4 antibodies binding this conserved RBD supersite showed potent neutralization of SARS-CoV-2 and all variants of concern. Structural analysis revealed that the neutralizing ability of cross-reactive antibodies was reserved only for those with an elongated CDRH3 that extends the antiparallel beta-sheet RBD core and orients the antibody light chain to obstruct ACE2-RBD interactions. These results identify a structurally defined pathway for vaccine strategies eliciting escape-resistant SARS-CoV-2 neutralizing antibodies.

14 May 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MSMandeep Singh
Mandeep Singh
RLRaymond H. Y. Louie
Raymond H. Y. Louie
JSJerome Samir
Jerome Samir
MFMatthew Field
Matthew Field
CMClaire Milthorpe
Claire Milthorpe
FLFabio Luciani
Fabio Luciani
Intestinal inflammation continues in a subset of patients with celiac disease despite a gluten-free diet. Here, by applying multi-omic single-cell analysis to duodenal biopsies, we found that low-grade malignancies with lymphoma driver mutations in patients with refractory celiac disease type 2 (RCD2) are comprised by surface CD3-negative (sCD3 − ) lymphocytes stalled at an innate lymphoid cell (ILC)–progenitor T cell stage undergoing extensive TRA , TRB , and TRD TCR recombination. In people with refractory celiac disease type 1 (RCD1), a disease currently lacking explanation, we identified sCD3 + T cells with lymphoma driver mutations in 6 of 10 individuals with RCD1 and in one of the patients with active, recently diagnosed celiac disease. Furthermore, the mutant T cells formed large TCRαβ clones and displayed inflammatory and cytotoxic molecular profiles. Thus, accumulation of lymphoma driver–mutated T cells and sCD3 − progenitors may contribute to chronic, nonresponsive celiac disease.